The Capital Group Companies, Inc. reduced its holding of INNOVENT BIO (01801) by approximately 3,327,400 shares at a price of around HK$31.55 per share.
On January 20th, The Capital Group Companies, Inc. reduced its holdings in Sino Biopharmaceutical (01801) by 3,327,405 shares, priced at 31.5469 Hong Kong dollars per share, for a total amount of approximately 105 million Hong Kong dollars.
According to the latest data from the Hong Kong Stock Exchange, on January 20, The Capital Group Companies, Inc. reduced its holdings of INNOVENT BIO (01801) by 3,327,405 shares, at a price of 31.5469 Hong Kong dollars per share, with a total amount of approximately 105 million Hong Kong dollars. After the reduction, the latest number of shares held is approximately 96,778,400 shares, with a shareholding proportion of 5.91%.
Related Articles
CUTIA-B (02487) repurchased 40,800 shares for HK$39,700 on October 5.
AI compute demand outlook viewed favorably; BNP Paribas raises target prices for NVIDIA Corporation (NVDA.US) and Intel Corporation (INTC.US), but remains cautious on the latter.
SINOPHARM TECH (08156) restores public float
CUTIA-B (02487) repurchased 40,800 shares for HK$39,700 on October 5.
AI compute demand outlook viewed favorably; BNP Paribas raises target prices for NVIDIA Corporation (NVDA.US) and Intel Corporation (INTC.US), but remains cautious on the latter.
SINOPHARM TECH (08156) restores public float
